Pasar al contenido principal

Sequential monitoring of the immune response against SARS-CoV-2 and other respiratory pathogens

IJC2020-044160-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Normal Residual Lymphoid Cell Populations in Blood as Surrogate Biomarker of the Leukemia Cell Kinetics in CLL BinetA/Rai 0

  • Solano, Fernando
  • Criado, Ignacio
  • Moreno, Nahir
  • Gomez-Gonzalez, Carlos
  • Lerma-Verdejo, Ana
  • Teodosio, Cristina
  • Martinez-Moya, María Dolores
  • Luts, Iryna
  • Contreras, María-Teresa
  • Oliva-Ariza, Guillermo
  • Fuentes-Herrero, Blanca
  • Serrano-Lozano, José Manuel
  • Almeida, Julia
  • Orfao, Alberto
Background/Objectives: Despite the current international prognostic index for chronic lymphocytic leukemia (CLL) being widely accepted and broadly used, it does not consider the kinetics of the B-cell clone over time. Here, we investigated the potential association between distinct features of leukemic cells and other immune cells in blood and the kinetics of clonal B-cells in CLL stage Binet A/Rai 0 (A/0) patients; Methods: Based on the leukemia cell kinetics, 69 CLL A/0 cases followed for a median of 105 months were classified as carrying stable (n = 53) vs. rapidly increasing in size (n = 16) CLL clones; Results: Patients with increasing CLL clones had a significantly higher risk of disease progression and shortened time to first therapy vs. those carrying stable B-cell clones (p ≤ 0.001). Strikingly, the distribution of various immune-cell populations in blood at diagnosis also differed significantly between the two groups, with lower Tαβ CD4+CD8lo cell counts (p = 0.03), a greater switched/unswitched memory B-cell ratio (p = 0.01), and higher plasma cell counts (p = 0.05) in CLL with increasing vs. stable clones. Multivariate analysis revealed that the number of circulating clonal B-cells (≥15 × 109/L) and Tαβ CD4+CD8lo cells (≤35 cells/µL), together with an IGHV unmutated gene status at diagnosis, were independent predictors of an increasing CLL clone; Conclusions: Altogether, these data suggest that the expansion of the CLL clone in stage A/0 patients may depend on both the intrinsic characteristics of CLL cells and the surrounding immune microenvironment., This research was funded by the “Early Cancer Research Initiative Network on MBL (ECRINM3)” ACCELERATOR award (CRUK -UK-, Fundación AECC -Spain- and Associazione Italiana per la Ricerca Sul Cancro -Italy-), by the CB16/12/00400 (CIBERONC) and PI22/00674 grants from the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, (Madrid, Spain) co-funded by FONDOS FEDER, and by the 0639-IDIAL-NET-3-3 grant (INTERREG POCTEP Spain-Portugal) from Fondo Europeo de Desarrollo Regional. I.C. was supported by Juan de la Cierva -Incorporación- grant (IJC2020-044160-I); Ministerio de Ciencia e Innovación, (Madrid, Spain). C.T. is the recipient of an USAL4EXCELLENCE fellowship, funded by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 101034371., Peer reviewed